Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOPAGO: Tpo-RA Discontinuation in ITP
NCT03119974Phase 4Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2017
- Primary completion
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of eltrombopag and romiplostim in immune thrombocytopenia (ITP), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Overall Response Rate at 24 weeks. Started Sep 2017; status: completed.
02
Drugs
eltrombopagromiplostim
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03119974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03119974.